Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11424419 | 0.98 | CHAT (0.46) | CHATACHEBCHEADORA3MAOA | |
| Iodide SCHEMBL11591341 | 0.98 | CHAT (0.46) | CHATACHEBCHEADORA3GRIN1 | |
| SCHEMBL14419209 | 0.82 | CHAT (0.43) | CHATACHEBCHEADORA3MAOA | |
| SCHEMBL5306354 | 0.81 | CHAT (0.50) | CHATACHEBCHEMAOAMAOB | |
| SCHEMBL12132102 | 0.76 | CCR9 (0.35) | — | |
| SCHEMBL10144617 | 0.76 | ALDH1A1 (0.34) | CHAT | |
| SCHEMBL19458284 | 0.76 | CHRNA7 (0.34) | MAOAMAOBGRIN1GRIN2AGRIN2B | |
| Sulcatin SCHEMBL2040356 | 0.74 | USP2 (0.39) | CHATACHEBCHEADORA3HDAC8 | |
| SCHEMBL10764076 | 0.72 | CA2 (0.35) | — | |
| SCHEMBL5297606 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3232455-B1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR ELECTRIC DOUBLE LAYER CAPACITORS | OTSUKA CHEMICAL CO LTD (JP) | 2023-10-25 | — | — | EP | disclosed |
| US-10914987-B2 | Complex and optical element | KYOTO UNIVERSITY (JP) | 2021-02-09 | — | — | US | disclosed |
| US-20200241336-A1 | COMPLEX AND OPTICAL ELEMENT | KYOTO UNIVERSITY (JP) | 2020-07-30 | — | — | US | disclosed |
| US-10593488-B2 | Nonaqueous electrolytic solution for electric double layer capacitors | OTSUKA CHEMICAL CO., LTD. (JP) | 2020-03-17 | — | — | US | disclosed |
| US-20170330700-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION FOR ELECTRIC DOUBLE LAYER CAPACITORS | OTSUKA CHEMICAL CO., LTD. (JP) | 2017-11-16 | — | — | US | disclosed |
| EP-3232455-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR ELECTRIC DOUBLE LAYER CAPACITORS | Otsuka Chemical Co., Ltd. (JP) | 2017-10-18 | — | — | EP | disclosed |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-1535913-B1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-7973030-B2 | Benzothiazepine and benzothiepine compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7803792-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | CHAT 721/4885ACHE 3147/4885BCHE 699/4885 |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | SLC10A1, SREBF1, SPTLC1 | CHAT 494/4885ACHE 2830/4885BCHE 92/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | CHAT 276/4885ACHE 2395/4885BCHE 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.